Eli Lilly Backs Rosy 2013 View Despite Patent Woes

Options Action 101 Web Extra: Is Eli Lilly's Rally Unhealthy? Is it time to get bearish on pharmaceutical giant Eli Lilly? Scott Nations has a way for you to cash in if the stock takes ill.

Analysts expect earnings of $3.72 per share on $22.87 billion in revenue.

Lilly's revenue slipped last year after it lost patent protection for its all-time best selling drug, the antipsychotic Zyprexa. That exposed the drug to cheaper generic competition.

This year, Lilly loses patent protection for the antidepressant Cymbalta in December and for the insulin Humalog in May.

Cymbalta replaced Zyprexa as Lilly's top seller.

View the original article here